Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | PPID | Q08752 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CFD | P00746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL714625 | 0.83 | EPHX1 (0.77) | EPHX1SMN1; SMN2P2RX7EPHX2TP53 | |
| SCHEMBL2549857 | 0.81 | PPID (0.62) | EPHX1SMN1; SMN2P2RX7LMNAPTPN1 | |
| SCHEMBL8640906 | 0.77 | LMNA (0.59) | SMN1; SMN2P2RX7EPHX2TP53LMNA | |
| SCHEMBL6033584 | 0.75 | TP53 (0.75) | EPHX1SMN1; SMN2EPHX2TP53LMNA | |
| SCHEMBL26406641 | 0.74 | EPHX1 (0.65) | EPHX1SMN1; SMN2P2RX7EPHX2TP53 | |
| SCHEMBL6435482 | 0.74 | EPHX2 (0.83) | EPHX1SMN1; SMN2P2RX7EPHX2TP53 | |
| SCHEMBL970225 | 0.74 | SMN1; SMN2 (0.70) | EPHX1SMN1; SMN2P2RX7EPHX2TP53 | |
| SCHEMBL7393991 | 0.74 | EPHX1 (0.65) | EPHX1SMN1; SMN2P2RX7EPHX2TP53 | |
| SCHEMBL1416043 | 0.74 | EPHX1 (0.65) | EPHX1SMN1; SMN2P2RX7EPHX2TP53 | |
| SCHEMBL372024 | 0.74 | MMP8 (0.60) | EPHX1SMN1; SMN2EPHX2TP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682996-B2 | Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions | Prism BioLab Co., Ltd. (JP) | 2017-06-20 | — | — | US | disclosed |
| US-20150376204-A1 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS | Prism BioLab Co., Ltd. (JP) | 2015-12-31 | — | — | US | disclosed |
| US-9126981-B2 | Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions | Prism BioLab Co., Ltd. (JP) | 2015-09-08 | — | — | US | disclosed |
| US-20140221657-A1 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS | PRISM BIOLAB CORPORATION (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20110263607-A1 | ALPHA HELIX MIMETICS IN THE TREATMENT OF CANCER | PRISM BIOLAB CORPORATION (JP) | 2011-10-27 | — | — | US | disclosed |
| EP-2346871-A1 | ALPHA HELIX MIMETICS IN THE TREATMENT OF CANCER | PRISM BioLab Corporation (JP) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010044485-A1 | ALPHA HELIX MIMETICS IN THE TREATMENT OF CANCER | PRISM BIOLAB CORPORATION (JP) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263607-A1 | ALPHA HELIX MIMETICS IN THE TREATMENT OF CANCER | COL1A1, HDGF, HCCS | EPHX1 534/4885SMN1; SMN2 1336/4885P2RX7 2595/4885 |
| US-20150376204-A1 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS | CREBBP, CTNNB1, CTNNA1 | EPHX1 1652/4885SMN1; SMN2 2633/4885P2RX7 2461/4885 |
| US-20140221657-A1 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS | CREBBP, CTNNB1, CTNNA1 | EPHX1 1652/4885SMN1; SMN2 2633/4885P2RX7 2461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.